Ken Song joined Omniome in 2017 as the Executive Chairman of the Board for Omniome. Ken’s experience spans clinical medicine, basic science research, venture capital, and entrepreneurship. Currently, Ken is the President and CEO of RayzeBio. Prior to RayzeBio he was President and CEO of Metacrine where he helped advance the company from a discovery organization to a clinical development company and positioned it for an eventual IPO. He was also the cofounder and CEO of Ariosa Diagnostics.
Before founding Ariosa, Ken was a venture capital investor at Venrock where he led investments in both private and public therapeutic, medical device, and diagnostic companies.
Ken trained in internal medicine at the University of California, San Francisco (UCSF) and then went on to specialize in gastroenterology and hepatology at the University of Washington along with a scientific fellowship at the Fred Hutchinson Cancer Center. He also spent several years as a consultant at McKinsey & Company focusing on early stage life-science companies.
Ken received his BS in Biology from the Massachusetts Institute of Technology, and his MD from UCSF.